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Bacterial vaginosis is a condition that affects millions of women worldwide. In most cases, it can be linked to 
the presence of Gardnerella vaginalis. Classical metronidazole treatments can lead to recurrence of 
bacterial vaginosis in more than 50% of cases due to its inability to fully eradicate the infection. This can be 
due to protective shielding of G. vaginalis by the biofilm it synthesizes. We showed previously that the co-
administration of recombinant human lysozyme, as a biofilm-degrading agent, with the antibiotic greatly 
improves its efficiency in vitro. Lysozyme purified from egg white is less expensive than recombinant human 
lysozyme and is commonly produced as an additive for human consumption. Our goal was to compare the 
effects of recombinant human lysozyme with that of egg white lysozyme alongside a conventional antibiotic 
treatment for bacterial vaginosis, using in vitro vaginal biofilm models. The results obtained here show that 
recombinant human lysozyme is a more efficient biofilm-degrading agent than egg white lysozyme and 
therefore constitutes a better choice as an anti-biofilm co-treatment for current vaginal antibiotherapy 
against G. vaginalis infection. 
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Bacterial vaginosis (BV) is the most common vaginal 
infection worldwide (Muzny and Schwebke, 2016), with 
an estimation of approximately 30% of women affected 
(Livengood, 2009). Its prevalence varies between ethnic 
groups and, to a lesser extent, between geographical 
zones (Kenyon et al., 2013). BV results from vaginal 
dysbiosis characterized by a shift in commensal 
saprophytic vaginal microflora dominated by lactobacilli, 
to a microflora dominated by facultative and strict 
anaerobes (Hillier, 1993). While still poorly understood 
and categorized due to probable multifactorial origins 
(Reid, 2018), BV is linked in most cases to the presence 
of Gardnerella vaginalis (Schwebke et al., 2014; Hay, 
2017), which can produce a biofilm that is not degraded 
by antibiotic treatment and that protects the bacteria 
against antibiotherapy (Thellin et al., 2016). One 
consequence is that numerous patients suffer from 
recurrent infections (Bradshaw et al., 2006; Sobel et al., 
2006). This occurs not only because antibiotics can be 
trapped by the biofilm matrix components and are 
therefore unable to efficiently reach all bacteria 
embedded in the biofilm (Nichols et al., 1988), potentially 
leading to antibiotic resistance phenomena; but also 
because the remaining biofilm could provide a shelter for 
new pathogens (Fux et al., 2006), leading to new 
infections. Bacteria inside biofilms can also be in a 
quiescent state, evading antibiotic effects (Gilbert et al., 
2002). We recently showed in vitro that the co-
administration of an antibiotic and recombinant human 
lysozyme, acting as a biofilm-degrading agent, could 
succeed in both degrading a G. vaginalis biofilm and 
killing all the bacteria that were present inside that biofilm 
(Thellin et al., 2016). Egg white lysozyme is less 
expensive  than  recombinant  human  lysozyme   and   is  
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already mass-produced for the food industry. Therefore, 
the aim of this article was to determine if egg white 
lysozyme or recombinant human lysozyme could be used 
as a co-treatment for antibiotherapies, and which would 
be more appropriate when administered in combination 
with antibiotics to treat vaginal pathological biofilms 
based on G. vaginalis. 
 
 




Four commercial lysozymes (one recombinant human lysozyme 
and three hen egg white lysozymes) were selected as models in the 
present work. The recombinant human lysozyme was coded HS 
(Sigma Aldrich, catalog number L1667, Belgium). The three hen 
egg white lysozyme are purified from chicken egg white and were 
coded OS (Sigma Aldrich, catalog number L6876, Belgium), OMS 
(BNLfood, Lysozyme Hypochloride – standard grade, Belgium), and 




Toxicity test on eukaryotic cells (MTS Assay) 
 
The potential toxicity of each of the lysozymes was tested on the 
vk2/E6E7 cell line (Fichorova et al., 1997), representative of the 
vaginal epithelial cell. For this, 20,000 cells were placed in each 
well of a flat bottom culture plate in Keratinocyte-SFM medium with 
L-glutamine without CaCl2 (Life Technologies, Belgium) 
supplemented with final concentrations of epidermal growth factor 
0.1 ng/ml, bovine pituitary extract 50 µg/ml, penicillin/streptomycin 
1%, and CaCl2 0.4 mM. Each culture condition was performed in 
triplicate. After 24 h, the cells reached 85% confluence. Lysozymes 
were added at the following concentrations, selected from previous 
work (Thellin et al., 2016): 500, 1,000, 2,000, 10,000, 20,000, 
30,000, 60,000 and 100,000 U/ml. Then, 20 µl of CellTiter 96 
AQueous One solution reagent (Promega Benelux, Belgium) was 
added after 24 h, 48 h, or 72 h, incubated for 1 h at 37°C then 
quantitated by optical density determination at 492 nm using an 
Epoch microplate spectrophotometer (BioTek Instruments, 
Winooski, VT, USA). For the 7-day incubation period, the culture 




Biofilm quantification and bactericidal assay 
 
A clinical strain of G. vaginalis was isolated by the LMM 
(Laboratoire de Microbiologie Medicale, Prof. Pierrette Melin, CHU 
of Liege, Belgium) from a vaginal sample, identified as G. vaginalis 
using a Bruker Microflex LT MALDI-TOF (Matrix Assisted Laser 
Desorption Ionisation – Time Of Flight) mass spectrometer running 
the MALDI Biotyper 3.1 software. This strain was coded GV10. The 
strain was maintained on Schaedler Agar with Vitamin K1 and 5% 
Sheep Blood (BD Benelux, Belgium) at 37°C under an anaerobic 
atmosphere. 
For biofilm generation, GV10 was resuspended in “Schaedler 
broth + Vit K3” (BioMerieux Benelux, Belgium) to a 1 McF density, 
and 100 µl of the suspension was added to each well of a 96-well 
plate. The biofilm was left to form over 24 h at 37°C under an 
anaerobic atmosphere. The broth was then replaced with fresh 
media containing the lysozymes at 100,000 U/ml. The plates were 
then incubated for 24 h in the presence of each lysozyme at 37°C 
under anaerobic conditions.  




Biofilm quantitation was performed by crystal violet staining, as 
follows. The supernatant of the wells was discarded. Then, 100 µl 
of methanol was added to each well for 15 min to fix the biofilm, 
removed, and the biofilm was left to dry at room temperature for 15 
min. Then, 100 µl of crystal violet 0.1% was added to the biofilms 
for 15 min, and wells were rinsed twice with 100 µl of deionized 
water. The crystal violet incorporated inside the biofilms was 
dissolved using 100 µl of acetic acid 33% and quantitated by optical 
density determination at 595 nm using an Epoch microplate 
spectrophotometer (BioTek Instruments, Winooski, VT, USA). 
The bactericidal assay was performed by colony forming unit 
(CFU) numeration, as follows. Biofilms were generated as 
described above. The supernatant of the culture wells was 
discarded. Biofilms were delicately washed with 100 µl of fresh 
media to remove non-adherent bacteria. Each biofilm was then 
mechanically disrupted in 200 µl of fresh media, then spread on 
SCH agar and left to grow for 48 h at 37°C under an anaerobic 
atmosphere before CFU numeration. 
 
 
Analysis of the lysozymes by SDS-PAGE 
 
Each of the four lysozymes was prepared in deionized water at both 
300,000 U/ml and 30,000 U/ml and added to 1 vol of Laemmli 
Sample buffer 2x (Bio-Rad, Belgium).The samples and molecular 
ladder (BioRad Precision Plus Protein Unstained Standards, Bio-
Rad, Belgium) were heated for 5 min at 100°C and loaded 
(20 µl/well) on 15% polyacrylamide gels, then subject to a sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis in running 
buffer (Tris 0.05 M, glycine 0.38 M, sodium dodecyl sulfate 0.1%, 






Statistical analyses were performed on results from toxicity tests 
and biofilm quantitation assays using respectively 2-way ANOVA 
followed by Bonferroni’s post-hoc test, and 1-way ANOVA followed 





Toxicity test on eukaryotic cells (MTS assay) 
 
Prior to assessing the anti-biofilm and bactericidal 
properties of the four lysozymes targeted in this study, we 
first tested their potential toxicity on the vk2/E6E7 cell 
line, as a model for the vaginal epithelium. 
A maximal concentration of 100,000 U/ml was selected 
based on the literature (Sudagidan and Yemenicioglu, 
2012). 
Results confirmed that none of the lysozymes 
significantly reduced cell viability, even at the highest 
tested concentration (Figure 1). Therefore, we chose to 




Biofilm quantitation (CV assay) 
 
The anti-biofilm activity of each of the lysozymes was 
assessed   on   24 h   biofilms   of   the   GV10   strain   of  






Figure 1. Cellular viability assessed by MTS assay after vk2/E6E7 cells were incubated for 24 h (A), 48 h (B), or 7 days (C) in the 
presence of dilutions of each of the four tested lysozymes. HS: recombinant human lysozyme; OS, OMS, and OPS: egg white 




G. vaginalis. The lysozymes were added to the biofilms, 
which were then incubated for 24 h, and the remaining 
biofilms were quantitated after treatment using a crystal 
violet assay. The results (Figure 2) show that each 
lysozyme was able to greatly reduce the amount of 
residual biofilm, but this effect was significantly (p < 0.01) 
stronger with the recombinant human lysozyme than with 




Lysozyme bactericidal activity (CFU numeration) 
 
The bactericidal activity of each of the lysozymes was 
assessed, as for the biofilm quantitation assay, on 24 h 
biofilms of the GV10 strain of G. vaginalis. The 
lysozymes were added to the biofilms for 24 h, then the 
residual bacteria of the remaining biofilms were 
harvested and grown on agar plates for CFU numeration. 
The results (Figure 3) show that, as for biofilm 
quantitation, each lysozyme was able to strongly reduce 
the amount of viable bacteria. In contrast to biofilm 
quantitation, this reduction was greater with the egg white 
lysozymes than with the recombinant human lysozyme. 
It is worth noting that, prior to CFU numeration, biofilm 
disruption during the biofilm resuspension step was much 
easier after HS treatment of the biofilm. No such impact 
was observed after any of the egg white lysozyme 
treatments, which showed no difference from the control 
condition without lysozyme for that parameter. 
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Figure 2. Biofilm quantitation by crystal violet assay. A 24 h biofilm is 
exposed to each lysozyme at 100,000 U/ml for 24 h then quantitated. 
HS: recombinant human lysozyme; OS, OMS, and OPS: egg white 


















Figure 3. CFU numeration of biofilm bacteria. A 24 h biofilm is exposed to 
each lysozyme at 100,000 U/ml for 24 h, then viable bacteria are 
numerated as CFUs after 48 h growth on agar plates. HS: recombinant 




Analysis of the lysozyme preparations 
 
The difference in results between lysozymes could be 
influenced by a loss of activity due to possible 
degradation of the lysozymes in the preparations. 
Therefore, we analyzed and compared the four 
commercial lysozymes on SDS-PAGE. After coloration of 
the proteins (Figure 4), we first observed that the main 
band was of the expected size of 14 kD for each 
lysozyme. We also observed that the amount of 14 kD 
protein was much higher for the same activity for OMS 
and OMP lysozymes. The bands for the OS and HS 
lysozymes were similar, if slightly more intense for OS 
than for HS. Smaller molecular weight bands were 
present at low intensity for each lysozyme, and were 
more visible when the 14 kD band was more intense. 
These smaller bands could be degraded forms of 
lysozymes,  but   their   intensities   are   negligible   when  






Figure 4. SDS-PAGE of 3,000 U (1X) and 300 U (1/10) of each lysozyme. HS: recombinant human lysozyme; 









Lysozymes are not expected to be toxic for human use. 
As an example, egg lysozyme is a common food additive 
used as a preservative (E1105). Egg white lysozyme is 
interesting for the food-processing industry due to its low 
cost, high yield, and anti-bacterial properties. In another 
work (Thellin et al., 2016), we observed that recombinant 
human lysozyme was able to lyse biofilms produced by 
various vaginal bacteria. We decided to test the ability of 
egg white lysozymes, alongside recombinant human 
lysozyme, to target a biofilm produced by G. vaginalis, 
the most frequently encountered pathological bacteria in 
cases of vaginosis. Three commercially-available egg 
white lysozymes from various sources were selected, 
along with previously tested recombinant human 
lysozyme. Our first goal was to confirm via an MTS-
based assay the absence of toxicity of these lysozymes 
on vaginal epithelial cells at doses that produce anti-
biofilm activities (Thellin et al., 2016). As expected, we 
observed no detectable cytotoxic effect on the vk2-E6E7 
epithelial cell line from each of the four lysozymes at any 
of the tested concentrations. However, while the 
lysozyme preparations did not exert cytotoxic effects on 
isolated vaginal epithelial cells, in vivo intravaginal 
administration of egg white lysozyme can generate 
inflammatory reactions (Pichler and Campi, 1992) against 
the egg lysozyme and/or other egg proteins. Egg 
lysozyme as food additive can also be unsuitable for 
consumption by persons who are allergic to eggs, 
accounting for 10 to 20% of egg allergy (Aabin et al., 
1996). Inversely, human lysozyme is not expected to 
trigger allergic reactions. The recombinant human 
lysozyme tested here has the same amino acid sequence 
as human lysozyme. It is therefore supposed that 
recombinant human lysozyme, contrary to egg white 
lysozyme, should not trigger an immune reaction. 
When testing the ability of the lysozymes to 
macroscopically degrade the G. vaginalis biofilm, the 
recombinant human lysozyme was found to be more 
effective than egg white lysozyme. On the other hand, the 
recombinant human lysozyme bactericidal effect on 
biofilm bacteria was unexpectedly lower than that of egg 
white lysozyme. The recombinant human lysozyme 
clearly has a higher anti-biofilm effect/bactericidal effect 
ratio than the egg lysozymes. This cannot be explained 
by a simple difference in the quality of the lysozyme 
preparations. The SDS-PAGE results showed that there 
is no significant protein degradation in these four 
lysozyme preparations, suggesting that observed effects 
were effectively due to the lysozymes. 
While lysozymes from both species can simultaneously 
target the biofilm and the bacteria, the recombinant 
human lysozyme seems to be more efficient in degrading 
G. vaginalis biofilm, while egg white lysozymes had a 
higher bactericidal effect. This suggests that human and 
egg lysozymes possess different activities and act on 
different targets, instead of one being more efficient than 
the other. Several hypotheses can be proposed to 
explain such results. Firstly, lysozyme inhibitors can be 
present in bacterial cell wall substrates (Nakimbugwe et 
al., 2006). Such inhibitors have different effects on 
different lysozymes, meaning that lysozyme inhibitors 
mainly active on human lysozyme and concentrated in 
the bacterial cell walls could explain our results. A second 
hypothesis is that lysozymes could act on Gram positive 
bacteria through other ways than via its enzymatic activity 
on peptidoglycan, notably through their cationic 
properties (Masschalck and Michiels, 2003). G. vaginalis 
is a Gram variable bacteria but its cell wall structure is 
close to Gram positive bacteria (Catlin, 1992), suggesting 
that such lysozyme cationic properties could 
hypothetically also act on G. vaginalis. A third hypothesis 
can be also proposed. Peptidoglycan is often considered 
to be the only target of lysozyme. But it has been known 
for decades that chitin can also be hydrolyzed by 





that lysozymes could also target one or several 
molecules other than peptidoglycan in G. vaginalis 
biofilms. It could also be possible that part of the biofilm 
degradation is due to a direct action of the lysozymes on 
the biofilm matrix components, and not solely a 
secondary consequence of the lysis of bacteria, involving 
lytic factors such as those described by Lewis (2000). 
The recombinant human lysozyme is therefore clearly 
preferable to egg white lysozyme when considering anti-
biofilm activity. While the egg white lysozyme seems to 
be more efficient than recombinant human lysozyme as a 
bactericidal agent, it is still far less potent than antibiotics 
such as clindamycin or metronidazole, widely used to 
treat vaginoses in vivo. Therefore the best combination of 
anti-biofilm and bactericidal agents against vaginal 
biofilms produced by G. vaginalis, the bacteria most often 
encountered in vaginosis cases, would be a combination 
of recombinant human lysozyme and antibiotic, with the 
condition that this lysozyme does not trigger an immune 





Considering first the potential absence of allergic or 
inflammatory reactions to recombinant human lysozyme; 
secondly its greater efficacy in biofilm degradation, 
allowing a better penetration and availability of co-
administered antibiotics; and thirdly the potential 
bactericidal effect of lysozyme/antibiotic combinations, 
recombinant human lysozyme is a better choice than egg 
white lysozyme as an anti-biofilm co-treatment for vaginal 
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